Cargando…
Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
Lenvatinib is a first-line standard treatment for advanced hepatocellular carcinoma (HCC) with better anti-tumor effects than sorafenib, as shown by greater inhibition of the kinases of fibroblast growth factor receptor and vascular endothelial growth factor (VEGF) receptor. This report describes a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036537/ https://www.ncbi.nlm.nih.gov/pubmed/32110202 http://dx.doi.org/10.1159/000505774 |
_version_ | 1783500238257913856 |
---|---|
author | Suzuki, Naomi Tajiri, Kazuto Futsukaichi, Yuka Tanaka, Shinichi Murayama, Aiko Entani, Toshiki Kobayashi, Saito Takahashi, Kosuke Fujii, Tsutomu Imura, Johji Yasuda, Ichiro |
author_facet | Suzuki, Naomi Tajiri, Kazuto Futsukaichi, Yuka Tanaka, Shinichi Murayama, Aiko Entani, Toshiki Kobayashi, Saito Takahashi, Kosuke Fujii, Tsutomu Imura, Johji Yasuda, Ichiro |
author_sort | Suzuki, Naomi |
collection | PubMed |
description | Lenvatinib is a first-line standard treatment for advanced hepatocellular carcinoma (HCC) with better anti-tumor effects than sorafenib, as shown by greater inhibition of the kinases of fibroblast growth factor receptor and vascular endothelial growth factor (VEGF) receptor. This report describes a patient with advanced HCC who experienced perforation of the small intestine 1 month after starting the treatment with lenvatinib. This patient likely had partial necrosis of a metastasis to the small intestine before starting lenvatinib treatment, with subsequent ischemic changes leading to perforation of the small intestine. Although metastasis of HCC to the small intestine is rare, patients with these metastases should be regarded as being at risk for perforation during lenvatinib treatment. |
format | Online Article Text |
id | pubmed-7036537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-70365372020-02-27 Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma Suzuki, Naomi Tajiri, Kazuto Futsukaichi, Yuka Tanaka, Shinichi Murayama, Aiko Entani, Toshiki Kobayashi, Saito Takahashi, Kosuke Fujii, Tsutomu Imura, Johji Yasuda, Ichiro Case Rep Gastroenterol Single Case Lenvatinib is a first-line standard treatment for advanced hepatocellular carcinoma (HCC) with better anti-tumor effects than sorafenib, as shown by greater inhibition of the kinases of fibroblast growth factor receptor and vascular endothelial growth factor (VEGF) receptor. This report describes a patient with advanced HCC who experienced perforation of the small intestine 1 month after starting the treatment with lenvatinib. This patient likely had partial necrosis of a metastasis to the small intestine before starting lenvatinib treatment, with subsequent ischemic changes leading to perforation of the small intestine. Although metastasis of HCC to the small intestine is rare, patients with these metastases should be regarded as being at risk for perforation during lenvatinib treatment. S. Karger AG 2020-02-05 /pmc/articles/PMC7036537/ /pubmed/32110202 http://dx.doi.org/10.1159/000505774 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Single Case Suzuki, Naomi Tajiri, Kazuto Futsukaichi, Yuka Tanaka, Shinichi Murayama, Aiko Entani, Toshiki Kobayashi, Saito Takahashi, Kosuke Fujii, Tsutomu Imura, Johji Yasuda, Ichiro Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma |
title | Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma |
title_full | Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma |
title_fullStr | Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma |
title_full_unstemmed | Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma |
title_short | Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma |
title_sort | perforation of the small intestine after introduction of lenvatinib in a patient with advanced hepatocellular carcinoma |
topic | Single Case |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036537/ https://www.ncbi.nlm.nih.gov/pubmed/32110202 http://dx.doi.org/10.1159/000505774 |
work_keys_str_mv | AT suzukinaomi perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma AT tajirikazuto perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma AT futsukaichiyuka perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma AT tanakashinichi perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma AT murayamaaiko perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma AT entanitoshiki perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma AT kobayashisaito perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma AT takahashikosuke perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma AT fujiitsutomu perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma AT imurajohji perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma AT yasudaichiro perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma |